Abstract: Provided is a multi-target compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism. The formula of the multi-target compound is as follows: A-L-B-L?-C. A and B are binding sites with a thrombin, C is a binding site with a platelet GPIIb/IIIa receptor, L is a first linking group, and L? is a second linking group. Also provided are a preparation method for the compound and use of the compound. The compound has the effects on inhibiting human thrombin activity and a platelet GPIIb/IIIa receptor in vitro, and has the effects on antiplatelet aggregation in vitro/in vivo, and anticoagulation and antithrombosis in vivo.

Abstract: The present invention provides a salt of a bile acid derivative, a crystal form thereof, a preparation method therefor and use thereof. The salt of a bile acid derivative, the crystal form thereof and a composition thereof provided by the present invention can improve cholestasis, reduce portal pressure, and improve liver function, and can be used for preparing medicaments for treating or alleviating chronic liver diseases, metabolic diseases, portal hypertension and related diseases.

Abstract: Provided are a compound for treating metabolic diseases having the structure as shown in formula (I) or formula (II), or a racemate, stereoisomer, geometric isomer, tautomer, solvate, hydrate, metabolite, pharmaceutically acceptable salt or prodrug thereof. The compound is an activator of FXR and/or a TGR5 receptor, and thus has the activity of activating FXR and/or a TGR5 receptor, and can be used in the preparation of drugs for treating chronic liver diseases, metabolic diseases or portal hypertension.

Abstract: The present disclosure relates to the field of drug technology, specifically to an active polypeptide compound, which is Y-ID-X or X-ID-Y; wherein Y is a PTH/PTHrP receptor agonist or an osteoclast inhibitor; ID is a peptide bond or a linker in the molecule, which links X to Y; and X is an osteogenic growth peptide receptor agonist, a bone marrow mesenchymal stem cell irritant or a hematopoietic stem cell irritant. The present disclosure also relates to a pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a medicament for preventing, treating or alleviating diseases or disorders related to osteogenic defects or bone mineral density decreasing.

Abstract: The present invention specifically relates to a class of compounds for treating nervous system diseases, which are compounds as shown by formula (I) or a stereoisomer, a geometric isomer, a tautomer, a solvate, a metabolite, a pharmaceutically acceptable salt of the compound as shown by formula (I) or a prodrug of the compound (I). The present invention also relates to a pharmaceutical composition comprising this class of compounds, and use of the compounds and pharmaceutical composition.

Abstract: Provided are a compound for treating metabolic diseases having the structure as shown in formula (I) or formula (II), or a racemate, stereoisomer, geometric isomer, tautomer, solvate, hydrate, metabolite, pharmaceutically acceptable salt or prodrug thereof. The compound is an activator of FXR and/or a TGR5 receptor, and thus has the activity of activating FXR and/or a TGR5 receptor, and can be used in the preparation of drugs for treating chronic liver diseases, metabolic diseases or portal hypertension.

Abstract: Provided is a multi-target compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism. The formula of the multi-target compound is as follows: A-L-B-L?-C. A and B are binding sites with a thrombin, C is a binding site with a platelet GPIIb/IIIa receptor, L is a first linking group, and U is a second linking group. Also provided are a preparation method for the compound and use of the compound. The compound has the effects on inhibiting human thrombin activity and a platelet GPIIb/IIIa receptor in vitro, and has the effects on antiplatelet aggregation in vitro/in vivo, and anticoagulation and antithrombosis in vivo.